NANOIMMUNOTECH SL

Their core work

Nanoimmunotech is a Spanish SME based in Vigo that develops nanoparticle-based diagnostic and therapeutic technologies. Their core work spans two directions: lab-on-a-chip biosensing devices using plasmonic thermal detection for rapid pathogen identification (e.g., Salmonella), and nanoparticle formulations for drug delivery — particularly lipid nanocarriers and polymer capsules for targeted therapies. They bridge the gap between nanomaterial science and biomedical application, contributing encapsulation and nanoformulation expertise to multi-partner research consortia.

What they specialise in

How they've shifted over time

Nanoimmunotech's early H2020 work (2015-2016) centered on diagnostic devices — their HEATSENS_S project for rapid pathogen detection via plasmonic sensing was their flagship, progressing from SME Phase 1 feasibility to Phase 2 scale-up. From 2017 onward, their participation shifted toward therapeutic nanoparticle applications: siRNA nanotherapy for inflammatory bowel diseases (NEW DEAL) and thermal bioimaging (NanoTBTech). This reflects a broadening from diagnostics-only into the therapeutic delivery space, where their nanoformulation skills found new applications.

Moving from diagnostic device development toward therapeutic nanocarrier formulations, suggesting future partnerships should look for their drug delivery and nanoencapsulation capabilities rather than only biosensing.

How they like to work

Nanoimmunotech operates in both leadership and specialist roles. They coordinated HEATSENS_S through both SME Instrument phases (showing they can drive a project from concept to commercialization), while joining four other consortia as a specialist partner contributing nanoparticle expertise. With 41 unique partners across 13 countries, they are well-connected for an SME of their size, indicating openness to new collaborations and an ability to integrate into diverse teams.

Nanoimmunotech has built a broad European network of 41 partners across 13 countries through 6 projects — a remarkably wide reach for a small company. Their partnerships span from marine biotechnology to pharmaceutical research, reflecting the cross-domain applicability of their nanoformulation skills.

What sets them apart

Nanoimmunotech combines two capabilities rarely found together in a single SME: plasmonic biosensing device development and nanoparticle therapeutic formulation. Their HEATSENS_S journey from SME Phase 1 to Phase 2 demonstrates they can take a technology from lab concept toward market — important for consortia needing a partner who understands both the science and the commercialization path. Based in Vigo (Galicia), they also bring a connection to marine and Atlantic-region research networks that is unusual for a nanomedicine company.

Highlights from their portfolio

• HEATSENS_S
  Their own product — a plasmonic thermal biosensing lab-on-a-chip — which they coordinated through both SME Instrument phases with EUR 1.4M total EC funding, showing strong commercialization ambition.
• NEW DEAL
  Demonstrates their therapeutic nanocarrier expertise: siRNA nanotherapy targeting inflammatory bowel diseases via nanostructured lipid carriers and polymer capsules for colon-targeted delivery.
• BIOCAPAN
  Largest single project contribution (EUR 853K) involving bioactive implantable capsules for immunosuppression-free pancreatic islet therapy — a high-impact medical application.